SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh its dominant position in the GLP-1 weight-loss market against intensifying competition and a recent high-profile clinical trial setback for its primary rival, Novo Nordisk. While the community is actively debating the timing of a potential oral drug launch, sentiment remains focused on the company's ability to maintain its market lead despite ongoing analyst downgrades and broader sector volatility.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently experiencing high volatility as investors weigh milestone euphoria against earnings anxiety, with market participants closely monitoring the company's progress on nuclear isotope licensing and Department of Energy approvals. Community discussions are centered on the upcoming business update, with traders debating whether these regulatory advancements will provide a significant catalyst or if the stock is being pumped ahead of potentially lackluster financial results.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is seeing intense volatility and active community debate as investors weigh strong earnings growth and AI infrastructure demand against market-wide profit-taking and valuation concerns. While many traders are buying the dip in anticipation of continued hyperscaler expansion, others remain cautious due to recent institutional selling and sector-wide sentiment shifts following major semiconductor conference announcements.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility during its Nasdaq debut, with investors debating the company's military-grade autonomous drone technology against concerns regarding its financial disclosures and typical IPO trading patterns. Market participants are actively tracking the stock's frequent trading halts while speculating on the long-term viability of its battlefield-tested software.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining attention as investors react to long-term clinical data published in JAMA Neurology, which reinforces the efficacy and durability of Briumvi in treating relapsing multiple sclerosis. The community remains focused on the company's revenue growth trajectory, potential for a buyout, and the strategic impact of its new national awareness campaign.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors digest a series of strategic pivots, including the acquisition of parking app SpotHero and the launch of 'Uber Autonomous Solutions' to court robotaxi developers. While some in the community express skepticism over heavy R&D spending and long-term viability, others view these movescoupled with significant insider buying by the CFOas a strong signal that the company is effectively positioning itself as the central, asset-light marketplace for future autonomous mobility.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is currently trending as investors speculate on a major tenant announcement following the strategic hiring of a CFO with extensive experience in data center financing. While community sentiment remains polarized between long-term holders eyeing a potential squeeze and skeptics demanding official PR to validate the company's behind-the-meter energy model, trading activity remains volatile as participants monitor volume for a sustained breakout.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge in trading volume and social interest as investors anticipate major announcements regarding its photonic engines and external light source products at the upcoming OFC and Nvidia GTC conferences. While some community members remain focused on the need for verified purchase orders and revenue, others view current price action as institutional accumulation in anticipation of a structural shift toward optical interconnects in AI infrastructure.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Investors in Fannie Mae (FNMA) are bracing for volatility as they weigh the potential for federal release and privatization against uncertainty over the timing of legislative action and the impact of the administration's current mortgage bond purchasing mandates. The community remains deeply divided, with many long-term holders citing interest from high-profile investors like Michael Burry and Bill Ackman as a reason to maintain conviction, while others express frustration over the lack of concrete timelines and the stock's recent downward price pressure.

Elbit Systems Ltd. engages in the defense and homeland security sector. It develops and supplies airborne, land and naval systems and products for defense, homeland security, and commercial applications. The firm also provides training and support services. The company was founded in 1996 and is headquartered in Haifa, Israel.

Elbit Systems Ltd.

Elbit Systems is trending as investors monitor ongoing contract wins in the global defense sector, while community discussions focus on its technical performance and valuation compared to industry peers. Market participants are also weighing the impact of its recent dividend increase and elevated demand for military technologies against a backdrop of regional geopolitical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Sanofi (NASDAQ:SNY) Declines By 17.4%

Sanofi (NASDAQ:SNY - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 6,560,718 shares, a drop of 17.4% from...

CSM Advisors LLC Acquires Shares of 386,534 Sanofi $SNY

CSM Advisors LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission...

XY Capital Ltd Acquires Shares of 33,970 Sanofi $SNY

XY Capital Ltd bought a new position in Sanofi (NASDAQ:SNY - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 33,970 shares...

Van ECK Associates Corp Sells 36,682 Shares of Sanofi $SNY

Van ECK Associates Corp reduced its holdings in Sanofi (NASDAQ:SNY - Free Report) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission...

SageView Advisory Group LLC Makes New Investment in Sanofi $SNY

SageView Advisory Group LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Barrow Hanley Mewhinney & Strauss LLC Lowers Holdings in Sanofi $SNY

Barrow Hanley Mewhinney & Strauss LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 2.1% during the 3rd quarter, according to the company in its most recent disclosure with the...

Grantham Mayo Van Otterloo & Co. LLC Buys 42,491 Shares of Sanofi $SNY

Grantham Mayo Van Otterloo & Co. LLC raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent 13F filing with the...

<ul class="summary-bullets"><li>The “go” decision was reached early, ahead of the company’s second quarter expected timeline.</li><li>The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, Truist said.</li><li>H.C. Wainwright increased its view of the probability of launch for claseprubart to 35% from a previous 26%.</li></ul>Shares of Dianthus Therapeutics, Inc. (DNTH) soared 19% on Monday after the company announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, boosting Wall Street optimism.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-early-go-decision-following">said</a> that the decision was based on an analysis of data from a part of its late-stage trial in which a response rate of 50% or greater was observed. Twenty or more responders were confirmed out of the first 40 participants to complete part A of the trial and no related serious infections or discontinuations were observed, the company said.The “go” decision was reached early, ahead of the company’s second quarter expected timeline, and confirmed by an independent Data Safety Monitoring Board review, it added.The decision supports continued development of claseprubart into the pivotal portion of the trial in CIDP, the company said. Dianthus Therapeutics said that it will maintain the dose as is in the part A portion of the trial and engage with regulators to remove a lower dose arm in the part B portion.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss. Other firms developing drugs for the condition include Sanofi (SNY) and Argenx SE (ARGX).<h2 class="st-heading-2">Wall Street Responds</h2>Truist raised the firm's price target on Dianthus to $110 from $63 and kept a ‘Buy’ rating on the shares. The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, the analyst told investors in a research note.H.C. Wainwright analyst Swayampakula Ramakanth, meanwhile, raised the firm's price target on Dianthus to $130 from $47 and kept a ‘Buy’ rating on the shares. The firm increased its view of the probability of launch for claseprubart to 35% from a previous 26% and also raised its price estimate to $450,000 per patient per annum compared to its prior $250,000 estimate.TD Cowen, which views Dianthus as "a viable takeout target," also kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DNTH stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/DNTH">DNTH stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jim-cramer-terrific-ai-stock-pick-gev-gets-double-upgrade/cZdVrjXRIIw">Jim Cramer's 'Terrific' AI Stock Pick Is Already Up 26% YTD, And It Just Received A Double Upgrade Today — Here's Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Dianthus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial. 

Equity

Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?

Merck faces continued pressure as Gardasil sales slump 39% in 2025, hit by weak China demand, with management expecting no rebound in 2026.

FY2026 EPS Estimates for Sanofi Reduced by Erste Group Bank

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Erste Group Bank dropped their FY2026 earnings estimates for shares of Sanofi in a report released on Wednesday, March 4th. Erste Group Bank...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Current Price	$44.29
Prev Close	$43.98
Open	$44.53
Dividend Yield	3.31%
50-Day Moving Average	$46.84
Beta	0.29
Avg. Volume	5.22M
PE Ratio	18.34

52-Week High	$59.17
52-Week Low	$43.34
Market Capitalization	$105.57B
EPS (Annual)	$2.41
Price to Book	1.27
Revenue Per Employee	$643,658.13

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNY News

SNYSanofi-Aventis